Page last updated: 2024-10-22

alpha-cyano-4-hydroxycinnamate and Osteosarcoma

alpha-cyano-4-hydroxycinnamate has been researched along with Osteosarcoma in 1 studies

alpha-cyano-4-hydroxycinnamate: specific inhibitor of pyruvate transport in rat liver mitochondria & human erythrocytes; structure

Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, Z1
Wu, MS1
Zou, C1
Tang, Q1
Lu, J1
Liu, D1
Wu, Y1
Yin, J1
Xie, X1
Shen, J1
Kang, T1
Wang, J1

Other Studies

1 other study available for alpha-cyano-4-hydroxycinnamate and Osteosarcoma

ArticleYear
Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway.
    Cancer letters, 2014, Jan-01, Volume: 342, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2014